Leukotriene antagonists as good as inhalers for asthma? (RCT, NEJM) - PulmCCM
Advertisement
May 202011
 

Most clinical trials for asthma drugs exclude ~95% of potential subjects and test under highly controlled conditions, limiting their results’ generalizability. Price et al publish results of 2 “pragmatic” open-label trials set in the real world. In #1, they randomized 300 symptomatic asthmatics in 53 U.K. primary care clinics to get either a leukotriene receptor antagonist (LTRA) or inhaled steroid as 1st-line therapy for asthma. In the other, 350 were randomized to LTRA or long-acting beta-agonist (LABA) as step-up/add-on therapy for asthma uncontrolled by an inhaled steroid.

In both trials, after 2 months the therapies were proved equivalent on the primary endpoint (asthma quality-of life scores) as determined by predefined criteria. At 2 years, equivalence could no longer be proved. As an editorial and “Perspective” point out, high rates of nonadherence (~70% adherence for LTRA, ~43% for inhalers) and crossover likely biased the study toward the null over the longer term. The U.K. government funded the study. (n=650) NEJM 2011;364:1695-1707.

Liked this post? Get a weekly email update (no spam, ever), and explore our library of clinical guidelines, practice updatesreview articles. and board review questions.

PulmCCM is an independent publication, not affiliated with or endorsed by any other organization, society or journal referenced on the website.

Leave a Comment